Adagio Therapeutics Overview
Latest ROE for Adagio Therapeutics: -59.27% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-59.27%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Adagio Therapeutics (ADGI) currently reports a ROE of -59.27%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Adagio Therapeutics's ROE history and peer comparisons.
Adagio Therapeutics's ROE of -59.27% is lower than the Healthcare sector average of 21.67%. That is roughly 373.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Adagio Therapeutics's current -59.27% should be judged against Healthcare norms (sector average: 21.67%) and against ADGI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -59.27%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Adagio Therapeutics, and consider following ADGI for alerts when major investors trade the stock.
Adagio Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -59.27% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADGI with unrelated industries.
